Harald H H W Schmidt

List of Publications by Year
in descending order

208 papers	25,042 citations	8208 78 h-index	8034 154 g-index
229 all docs	229 docs citations	229 times ranked	21550 citing authors

#	Article	IF	Citations
1	Cyclic GMP modulating drugs in cardiovascular diseases: mechanism-based network pharmacology. Cardiovascular Research, 2022, 118, 2085-2102.	1.8	23
2	Implication of type 4 NADPH oxidase (NOX4) in tauopathy. Redox Biology, 2022, 49, 102210.	3.9	12
3	The regulatory network architecture of cardiometabolic diseases. Nature Genetics, 2022, 54, 2-3.	9.4	5
4	Network pharmacology: curing causal mechanisms instead of treating symptoms. Trends in Pharmacological Sciences, 2022, 43, 136-150.	4.0	294
5	Independent of Renox, NOX5 Promotes Renal Inflammation and Fibrosis in Diabetes by Activating ROS-Sensitive Pathways. Diabetes, 2022, 71, 1282-1298.	0.3	14
6	Cancer driver drug interaction explorer. Nucleic Acids Research, 2022, 50, W138-W144.	6.5	9
7	Endothelial reactive oxygen-forming NADPH oxidase 5 is a possible player in diabetic aortic aneurysm but not atherosclerosis. Scientific Reports, 2022, 12, .	1.6	6
8	Pharmacological activation of soluble guanylate cyclase improves vascular graft function. Interactive Cardiovascular and Thoracic Surgery, 2021, 32, 803-811.	0.5	3
9	An Early Stage Researcher's Primer on Systems Medicine Terminology. Network and Systems Medicine, 2021, 4, 2-50.	2.7	9
10	Network medicine for disease module identification and drug repurposing with the NeDRex platform. Nature Communications, 2021, 12, 6848.	5.8	39
11	Isoform-selective NADPH oxidase inhibitor panel for pharmacological target validation. Free Radical Biology and Medicine, 2020, 148, 60-69.	1.3	50
12	Network and Systems Medicine: Position Paper of the European Collaboration on Science and Technology Action on Open Multiscale Systems Medicine. Network and Systems Medicine, 2020, 3, 67-90.	2.7	18
13	NOX Inhibitors: From Bench to Naxibs to Bedside. Handbook of Experimental Pharmacology, 2020, 264, 145-168.	0.9	38
14	Network Medicine-Based Unbiased Disease Modules for Drug and Diagnostic Target Identification in ROSopathies. Handbook of Experimental Pharmacology, 2020, 264, 49-68.	0.9	7
15	On the Clinical Pharmacology of Reactive Oxygen Species. Pharmacological Reviews, 2020, 72, 801-828.	7.1	70
16	Nitric Oxide Synthase Inhibitors into the Clinic at Last. Handbook of Experimental Pharmacology, 2020, 264, 169-204.	0.9	10
17	Reactive Oxygen-Forming Nox5 Links Vascular Smooth Muscle Cell Phenotypic Switching and Extracellular Vesicle-Mediated Vascular Calcification. Circulation Research, 2020, 127, 911-927.	2.0	104
18	Non-canonical chemical feedback self-limits nitric oxide-cyclic GMP signaling in health and disease. Scientific Reports, 2020, 10, 10012.	1.6	10

#	Article	IF	Citations
19	Molecular networks in Network Medicine: Development and applications. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 2020, 12, e1489.	6.6	128
20	De Novo and Supervised Endophenotyping Using Network-Guided Ensemble Learning. Systems Medicine (New Rochelle, N Y), 2020, 3, 8-21.	1.4	9
21	NOX5-induced uncoupling of endothelial NO synthase is a causal mechanism and theragnostic target of an age-related hypertension endotype. PLoS Biology, 2020, 18, e3000885.	2.6	23
22	Title is missing!. , 2020, 18, e3000885.		0
23	Title is missing!. , 2020, 18, e3000885.		0
24	Title is missing!. , 2020, 18, e3000885.		0
25	Title is missing!. , 2020, 18, e3000885.		0
26	Title is missing!. , 2020, 18, e3000885.		0
27	Title is missing!. , 2020, 18, e3000885.		0
28	Title is missing!. , 2020, 18, e3000885.		0
29	Red Blood Cellâ€“Derived Nitric Oxide Bioactivity and Hypoxic Vasodilation. Circulation, 2019, 139, 2664-2667.	1.6	12
30	From single drug targets to synergistic network pharmacology in ischemic stroke. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 7129-7136.	3.3	132
31	Reactive Oxygen Comes of Age: Mechanism-Based Therapy of Diabetic End-Organ Damage. Trends in Endocrinology and Metabolism, 2019, 30, 312-327.	3.1	50
32	Time-Resolved Systems Medicine Reveals Viral Infection-Modulating Host Targets. Systems Medicine (New Rochelle, N Y), 2019, 2, 1-9.	1.4	14
33	E. coligene regulatory networks are inconsistent with gene expression data. Nucleic Acids Research, 2019, 47, 85-92.	6.5	60
34	Community effort endorsing multiscale modelling, multiscale data science and multiscale computing for systems medicine. Briefings in Bioinformatics, 2019, 20, 1057-1062.	3.2	15
35	Calcium-dependent blood-brain barrier breakdown by NOX5 limits postreperfusion benefit in stroke. Journal of Clinical Investigation, 2019, 129, 1772-1778.	3.9	55
36	Transcription Factor NRF2 as a Therapeutic Target for Chronic Diseases: A Systems Medicine Approach. Pharmacological Reviews, 2018, 70, 348-383.	7.1	441

#	Article	IF	Citations
37	The End of Medicine as We Know It: Introduction to the New Journal, Systems Medicine. Systems Medicine (New Rochelle, N Y), 2018, 1, 1-2.	1.4	8
38	A diseasome cluster-based drug repurposing of soluble guanylate cyclase activators from smooth muscle relaxation to direct neuroprotection. Npj Systems Biology and Applications, 2018, 4, 8.	1.4	45
39	Targeting Phosphodiesterase-5 by Vardenafil Improves Vascular Graft Function. European Journal of Vascular and Endovascular Surgery, 2018, 56, 256-263.	0.8	8
40	Expert Panel Discusses the Importance of Systems Medicine. Systems Medicine (New Rochelle, N Y), 2018, 1, 3-8.	1.4	1
41	Proximal Pathway Enrichment Analysis for Targeting Comorbid Diseases via Network Endopharmacology. Pharmaceuticals, 2018, 11, 61.	1.7	32
42	Is internal thoracic artery resistant to reperfusion injury? Evaluation of the storage of free internal thoracic artery grafts. Journal of Thoracic and Cardiovascular Surgery, 2018, 156, 1460-1469.	0.4	12
43	Combined NOX1/4 inhibition with GKT137831 in mice provides dose-dependent reno- and atheroprotection even in established micro- and macrovascular disease. Diabetologia, 2017, 60, 927-937.	2.9	85
44	European contribution to the study of ROS: A summary of the findings and prospects for the future from the COST action BM1203 (EU-ROS). Redox Biology, 2017, 13, 94-162.	3.9	242
45	NOX4-dependent neuronal autotoxicity and BBB breakdown explain the superior sensitivity of the brain to ischemic damage. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 12315-12320.	3.3	112
46	The oxidative stress theory of disease: levels of evidence and epistemological aspects. British Journal of Pharmacology, 2017, 174, 1784-1796.	2.7	126
47	NOX4 is an early initiator of neuropathic pain. Experimental Neurology, 2017, 288, 94-103.	2.0	35
48	Imaging Reactive Oxygen Species-Induced Modifications in Living Systems. Antioxidants and Redox Signaling, 2016, 24, 939-958.	2.5	43
49	Differential effects of NOX4 and NOX1 on immune cell-mediated inflammation in the aortic sinus of diabetic ApoEâ^'/â^' mice. Clinical Science, 2016, 130, 1363-1374.	1.8	33
50	NOX4-derived reactive oxygen species limit fibrosis and inhibit proliferation of vascular smooth muscle cells in diabetic atherosclerosis. Free Radical Biology and Medicine, 2016, 97, 556-567.	1.3	55
51	Clinical relevance of cyclic GMP modulators: A translational success story of network pharmacology. Clinical Pharmacology and Therapeutics, 2016, 99, 360-362.	2.3	19
52	Intraoperative Quantitative Mitral Valve Analysis Using Optical Tracking Technology. Annals of Thoracic Surgery, 2016, 101, 1950-1956.	0.7	14
53	NOS knockout or inhibition but not disrupting PSD-95-NOS interaction protect against ischemic brain damage. Journal of Cerebral Blood Flow and Metabolism, 2016, 36, 1508-1512.	2.4	18
54	Reactive Oxygen Species Can Provide Atheroprotection via NOX4-Dependent Inhibition of Inflammation and Vascular Remodeling. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 295-307.	1.1	147

#	Article	IF	Citations
55	Podocyte-specific Nox4 deletion affords renoprotection in a mouse model of diabetic nephropathy. Diabetologia, 2016, 59, 379-389.	2.9	114
56	TiProtec preserves endothelial function in a rat model. Journal of Surgical Research, 2016, 200, 346-355.	0.8	18
57	A combined pre-clinical meta-analysis and randomized confirmatory trial approach to improve data validity for therapeutic target validation. Scientific Reports, 2015, 5, 13428.	1.6	30
58	Endothelial Dysfunction of Bypass Graft: Direct Comparison of In Vitro and In Vivo Models of Ischemia-Reperfusion Injury. PLoS ONE, 2015, 10, e0124025.	1.1	14
59	Gender differences in the effect of cardiovascular drugs: a position document of the Working Group on Pharmacology and Drug Therapy of the ESC: FigureÂ1. European Heart Journal, 2015, 36, 2677-2680.	1.0	131
60	NOX4 in Mitochondria: Yeast Two-Hybrid-Based Interaction with Complex I Without Relevance for Basal Reactive Oxygen Species?. Antioxidants and Redox Signaling, 2015, 23, 1106-1112.	2.5	42
61	Antioxidants in Translational Medicine. Antioxidants and Redox Signaling, 2015, 23, 1130-1143.	2.5	201
62	Clinical Relevance of Biomarkers of Oxidative Stress. Antioxidants and Redox Signaling, 2015, 23, 1144-1170.	2.5	604
63	Pharmacology and Clinical Drug Candidates in Redox Medicine. Antioxidants and Redox Signaling, 2015, 23, 1113-1129.	2.5	75
64	Reactive Oxygen-Related Diseases: Therapeutic Targets and Emerging Clinical Indications. Antioxidants and Redox Signaling, 2015, 23, 1171-1185.	2.5	120
65	Evolution of NADPH Oxidase Inhibitors: Selectivity and Mechanisms for Target Engagement. Antioxidants and Redox Signaling, 2015, 23, 406-427.	2.5	410
66	Nox-4 deletion reduces oxidative stress and injury by PKC-Î±-associated mechanisms in diabetic nephropathy. Physiological Reports, 2014, 2, e12192.	0.7	88
67	NADPH Oxidase, NOX1, Mediates Vascular Injury in Ischemic Retinopathy. Antioxidants and Redox Signaling, 2014, 20, 2726-2740.	2.5	104
68	Genetic Targeting or Pharmacologic Inhibition of NADPH Oxidase Nox4 Provides Renoprotection in Long-Term Diabetic Nephropathy. Journal of the American Society of Nephrology: JASN, 2014, 25, 1237-1254.	3.0	301
69	Increases survival by apo-sGC activation via post-stroke blood brain barrier stabilisation and anti-inflammation. BMC Pharmacology & Toxicology, 2013, 14, .	1.0	1
70	Neuroprotection After Stroke by Targeting NOX4 As a Source of Oxidative Stress. Antioxidants and Redox Signaling, 2013, 18, 1418-1427.	2.5	126
71	NADPH Oxidase 1 Plays a Key Role in Diabetes Mellitusâ€“Accelerated Atherosclerosis. Circulation, 2013, 127, 1888-1902.	1.6	325
72	Comment on: Sukumar et al. Nox2 NADPH Oxidase Has a Critical Role in Insulin Resistance-Related Endothelial Cell Dysfunction. Diabetes 2013;62:2130-2134. Diabetes, 2013, 62, e30-e30.	0.3	2

#	Article	IF	Citations
73	Carrots, Sticks and False Carrots: How high should weight control wellness incentives be? Findings from a population-level experiment. Frontiers in Public Health Services & Systems Research, 2013, 2, .	0.0	0
74	NOX4 Is a Janus-Faced Reactive Oxygen Species Generating NADPH Oxidase. Circulation Research, 2012, 111, e15-6; author reply e17-8.	2.0	21
75	VAS2870 is a pan-NADPH oxidase inhibitor. Cellular and Molecular Life Sciences, 2012, 69, 3159-3160.	2.4	57
76	Activation of TRPC6 channels is essential for lung ischaemiaâ€“reperfusion induced oedema in mice. Nature Communications, 2012, 3, 649.	5.8	162
77	The 1027th target candidate in stroke: Will NADPH oxidase hold up?. Experimental & Translational Stroke Medicine, 2012, 4, 11.	3.2	37
78	The NOX toolbox: validating the role of NADPH oxidases in physiology and disease. Cellular and Molecular Life Sciences, 2012, 69, 2327-2343.	2.4	321
79	Measuring oxidative burden and predicting pharmacological response in coronary artery disease patients with a novel direct activator of haem-free/oxidised sGC. Atherosclerosis, 2011, 218, 431-434.	0.4	22
80	Endothelial dysfunction after right coronary artery remodeling: a new pathogenetic role of eNOS uncoupling?. Journal of Applied Physiology, 2011, 111, 329-329.	1.2	0
81	Pathogenetic role of eNOS uncoupling in cardiopulmonary disorders. Free Radical Biology and Medicine, 2011, 50, 765-776.	1.3	123
82	Modulating endothelial nitric oxide synthase: a new cardiovascular therapeutic strategy. American Journal of Physiology - Heart and Circulatory Physiology, 2011, 301, H634-H646.	1.5	71
83	Fluorescence Dequenching Makes Haem-Free Soluble Guanylate Cyclase Detectable in Living Cells. PLoS ONE, 2011, 6, e23596.	1.1	29
84	Folic Acid as a Cardiovascular Drug: Dose Matters. American Journal of Cardiology, 2010, 106, 1673-1674.	0.7	1
85	Oxidative Stress and Endothelial Dysfunction in Aortas of Aged Spontaneously Hypertensive Rats by NOX1/2 Is Reversed by NADPH Oxidase Inhibition. Hypertension, 2010, 56, 490-497.	1.3	151
86	Post-Stroke Inhibition of Induced NADPH Oxidase Type 4 Prevents Oxidative Stress and Neurodegeneration. PLoS Biology, 2010, 8, e1000479.	2.6	377
87	Diagnosis and individual treatment of cardiovascular diseases: targeting vascular oxidative stress. Expert Review of Clinical Pharmacology, 2010, 3, 639-648.	1.3	5
88	Good Stress, Bad Stress. Deutsches Ärzteblatt International, 2009, 106, 677-84.	0.6	9
89	Nitric Oxideâ€“Independent Vasodilator Rescues Heme-Oxidized Soluble Guanylate Cyclase From Proteasomal Degradation. Circulation Research, 2009, 105, 33-41.	2.0	98
90	NO- and Haem-Independent Soluble Guanylate Cyclase Activators. Handbook of Experimental Pharmacology, 2009, , 309-339.	0.9	131

#	Article	IF	Citations
91	Translating the oxidative stress hypothesis into the clinic: NOX versus NOS. Journal of Molecular Medicine, 2009, 87, 1071-1076.	1.7	52
92	Distinct molecular requirements for activation or stabilization of soluble guanylyl cyclase upon haem oxidation-induced degradation. BMC Pharmacology, 2009, 9, .	0.4	1
93	cGMP in the Vasculature. Handbook of Experimental Pharmacology, 2009, , 447-467.	0.9	44
94	Heat shock protein 90 regulates stabilization rather than activation of soluble guanylate cyclase. FEBS Letters, 2008, 582, 327-331.	1.3	29
95	Distinct roles of Nox1 and Nox4 in basal and angiotensin II-stimulated superoxide and hydrogen peroxide production. Free Radical Biology and Medicine, 2008, 45, 1340-1351.	1.3	342
96	NADPH oxidases in the vasculature: Molecular features, roles in disease and pharmacological inhibition. , 2008, 120, 254-291.		221
97	Characterization of the Human Î±1Î²1 Soluble Guanylyl Cyclase Promoter. Journal of Biological Chemistry, 2008, 283, 20027-20036.	1.6	23
98	Apocynin Is Not an Inhibitor of Vascular NADPH Oxidases but an Antioxidant. Hypertension, 2008, 51, 211-217.	1.3	677
99	Sildenafil in hypoxic pulmonary hypertension potentiates a compensatory upâ€regulation of NOâ€cGMP signaling. FASEB Journal, 2008, 22, 30-40.	0.2	36
100	Effect of Gender on NADPH-Oxidase Activity, Expression, and Function in the Cerebral Circulation. Stroke, 2007, 38, 2142-2149.	1.0	133
101	Dimerization Region of Soluble Guanylate Cyclase Characterized by Bimolecular Fluorescence Complementation in Vivo. Molecular Pharmacology, 2007, 72, 1181-1190.	1.0	45
102	Hypoxia-Dependent Regulation of Nonphagocytic NADPH Oxidase Subunit NOX4 in the Pulmonary Vasculature. Circulation Research, 2007, 101, 258-267.	2.0	317
103	Role of the Multidrug Resistance Protein-1 in Hypertension and Vascular Dysfunction Caused by Angiotensin II. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 762-768.	1.1	86
104	The â€˜Aâ€™s and â€˜Oâ€™s of NADPH oxidase regulation: A commentary on â€œSubcellular localization and function of alternatively spliced Noxo1 isoformsâ€• Free Radical Biology and Medicine, 2007, 42, 175-179.	1.3	53
105	Gender influences NADPH oxidase in the cerebral circulation. FASEB Journal, 2007, 21, A1170.	0.2	0
106	Identification of residues crucially involved in soluble guanylate cyclase activation. FEBS Letters, 2006, 580, 4205-4213.	1.3	29
107	Novel Nox inhibitor of oxLDL-induced reactive oxygen species formation in human endothelial cells. Biochemical and Biophysical Research Communications, 2006, 344, 200-205.	1.0	120
108	NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nature Reviews Drug Discovery, 2006, 5, 755-768.	21.5	623

#	Article	IF	Citations
109	Activation of Soluble Guanylate Cyclase Reverses Experimental Pulmonary Hypertension and Vascular Remodeling. Circulation, 2006, 113, 286-295.	1.6	208
110	Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. Journal of Clinical Investigation, 2006, 116, 2552-2561.	3.9	390
111	Beyond NO and heme: biochemical and pharmacological opportunities. BMC Pharmacology, 2005, 5, S18.	0.4	2
112	Hemodynamic and biochemical adaptations to vascular smooth muscle overexpression of p22phox in mice. American Journal of Physiology - Heart and Circulatory Physiology, 2005, 288, H7-H12.	1.5	77
113	NADPH Oxidase Activity and Function Are Profoundly Greater in Cerebral Versus Systemic Arteries. Circulation Research, 2005, 97, 1055-1062.	2.0	198
114	Nox1 Overexpression Potentiates Angiotensin II-Induced Hypertension and Vascular Smooth Muscle Hypertrophy in Transgenic Mice. Circulation, 2005, 112, 2668-2676.	1.6	396
115	Structural Analysis of Isoform-Specific Inhibitors Targeting the Tetrahydrobiopterin Binding Site of Human Nitric Oxide Synthases. Journal of Medicinal Chemistry, 2005, 48, 4783-4792.	2.9	31
116	Direct Interaction of the Novel Nox Proteins with p22phox Is Required for the Formation of a Functionally Active NADPH Oxidase. Journal of Biological Chemistry, 2004, 279, 45935-45941.	1.6	468
117	Reduced cGMP signaling associated with neointimal proliferation and vascular dysfunction in late-stage atherosclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 16671-16676.	3.3	92
118	A Constitutive NADPH Oxidase-Like System Containing gp91phox Homologs in Human Keratinocytes. Journal of Investigative Dermatology, 2004, 122, 1000-1009.	0.3	75
119	Upregulation of NAD(P)H oxidase 1 in hypoxia activates hypoxia-inducible factor 1 via increase in reactive oxygen species. Free Radical Biology and Medicine, 2004, 36, 1279-1288.	1.3	183
120	Distribution of soluble guanylyl cyclase in the rat brain. Journal of Comparative Neurology, 2004, 472, 437-448.	0.9	87
121	Experimental autoimmune encephalomyelitis in mice with a targeted deletion of the inducible nitric oxide synthase gene: increased T-helper 1 response. Neuroscience Letters, 2004, 358, 58-62.	1.0	27
122	Protective role of the cytokine-inducible isoform of nitric oxide synthase induction and nitrosative stress in experimental autoimmune encephalomyelitis of the DA rat. Journal of Neuroscience Research, 2003, 73, 198-205.	1.3	37
123	L-Arginine counteracts nitric oxide deficiency and improves the recovery phase of ischemic acute renal failure in rats. Kidney International, 2003, 64, 216-225.	2.6	75
124	There's NO binding like NOS binding: Protein-protein interactions in NO/cGMP signaling. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 16510-16512.	3.3	73
125	Susceptibility to Cardiac Ischemia/Reperfusion Injury Is Modulated by Chronic Estrogen Status. Journal of Cardiovascular Pharmacology, 2002, 40, 420-428.	0.8	33
126	In vitro detection of nitric oxide and nitroxyl by electron paramagnetic resonance. Methods in Enzymology, 2002, 359, 18-27.	0.4	5

#	Article	IF	Citations
127	Structural Requirements for Inhibition of the Neuronal Nitric Oxide Synthase (NOS-I):Â 3D-QSAR Analysis of 4-Oxo- and 4-Amino-Pteridine-Based Inhibitors. Journal of Medicinal Chemistry, 2002, 45, 2923-2941.	2.9	31
128	Phosphorylation of Blood Vessel Vasodilator-Stimulated Phosphoprotein at Serine 239 as a Functional Biochemical Marker of Endothelial Nitric Oxide/Cyclic GMP Signaling. Molecular Pharmacology, 2002, 61, 312-319.	1.0	55
129	Type I nitric oxide synthase in the human lung is predominantly expressed in capillary endothelial cells. Respiration Physiology, 2002, 129, 367-374.	2.8	31
130	Synaptic Localization of Nitric Oxide Synthase and Soluble Guanylyl Cyclase in the Hippocampus. Journal of Neuroscience, 2002, 22, 8961-8970.	1.7	180
131	Regional distribution of protein and activity of the nitric oxide receptor, soluble guanylyl cyclase, in rat brain suggests multiple mechanisms of regulation. Brain Research, 2002, 950, 148-154.	1.1	24
132	L-Arginine deficiency and supplementation in experimental acute renal failure and in human kidney transplantation. Kidney International, 2002, 61, 1423-1432.	2.6	71
133	Calcium-dependent membrane association sensitizes soluble guanylyl cyclase to nitric oxide. Nature Cell Biology, 2002, 4, 307-311.	4.6	142
134	Pterin interactions with distinct reductase activities of NO synthase. Biochemical Journal, 2001, 356, 43-51.	1.7	7
135	Immunohistochemical localization of nitric oxide synthase and soluble guanylyl cyclase in the ventral cochlear nucleus of the rat. Journal of Comparative Neurology, 2001, 431, 1-10.	0.9	23
136	Substance P and nitric oxide signaling in cerebral cortex: Anatomical evidence for reciprocal signaling between two classes of interneurons. Journal of Comparative Neurology, 2001, 441, 288-301.	0.9	61
137	Regional and age-dependent expression of the nitric oxide receptor, soluble guanylyl cyclase, in the human brain. Brain Research, 2001, 907, 54-60.	1.1	34
138	Nitroxyl oxidizes NADPH in a superoxide dismutase inhibitable manner. Free Radical Biology and Medicine, 2001, 30, 803-808.	1.3	37
139	Upregulation of the vascular NAD(P)H-oxidase isoforms Nox1 and Nox4 by the renin-angiotensin system in vitro and in vivo. Free Radical Biology and Medicine, 2001, 31, 1456-1464.	1.3	244
140	Pterin interactions with distinct reductase activities of NO synthase. Biochemical Journal, 2001, 356, 43.	1.7	7
141	Allosteric regulation of neuronal nitric oxide synthase by tetrahydrobiopterin and suppression of auto-damaging superoxide. Biochemical Journal, 2000, 346, 767.	1.7	15
142	Allosteric regulation of neuronal nitric oxide synthase by tetrahydrobiopterin and suppression of auto-damaging superoxide. Biochemical Journal, 2000, 346, 767-776.	1.7	44
143	Electron-paramagnetic resonance spectroscopy using N-methyl-d-glucamine dithiocarbamate iron cannot discriminate between nitric oxide and nitroxyl: implications for the detection of reaction products for nitric oxide synthase. Free Radical Biology and Medicine, 2000, 28, 739-742.	1.3	43
144	Endothelial Nitric-oxide Synthase (Type III) Is Activated and Becomes Calcium Independent upon Phosphorylation by Cyclic Nucleotide-dependent Protein Kinases. Journal of Biological Chemistry, 2000, 275, 5179-5187.	1.6	256

#	Article	IF	Citations
145	The Soluble Guanylyl Cyclase Inhibitor 1H-[1,2,4]Oxadiazolo[4,3,-a]quinoxalin-1-one Is a Nonselective Heme Protein Inhibitor of Nitric Oxide Synthase and Other Cytochrome P-450 Enzymes Involved in Nitric Oxide Donor Bioactivation. Molecular Pharmacology, 1999, 56, 243-253.	1.0	154
146	Downregulation of Soluble Guanylyl Cyclase in Young and Aging Spontaneously Hypertensive Rats. Circulation Research, 1999, 85, 534-541.	2.0	197
147	Homodimerization of Soluble Guanylyl Cyclase Subunits. Journal of Biological Chemistry, 1999, 274, 18149-18152.	1.6	86
148	Tetrahydrobiopterin Inhibits Monomerization and Is Consumed during Catalysis in Neuronal NO Synthase. Journal of Biological Chemistry, 1999, 274, 24921-24929.	1.6	105
149	Effects of the soluble guanylyl cyclase activator, YC-1, on vascular tone, cyclic GMP levels and phosphodiesterase activity. British Journal of Pharmacology, 1999, 127, 195-203.	2.7	162
150	Nitric oxide synthase-containing projections to the ventrobasal thalamus in the rat. Anatomy and Embryology, 1999, 200, 265-281.	1.5	34
151	Cloning and functional expression of the calmodulin gene from Toxoplasma gondii. Molecular and Biochemical Parasitology, 1999, 99, 295-299.	0.5	15
152	Biochemical and functional characterization of nitric oxide synthase III gene transfer using a replication-deficient adenoviral vector. Biochemical Pharmacology, 1999, 58, 1155-1166.	2.0	15
153	Inhibition of Neuronal Nitric Oxide Synthase by 4-Amino Pteridine Derivatives:â€‰Structureâ^'Activity Relationship of Antagonists of (6R)-5,6,7,8-Tetrahydrobiopterin Cofactor. Journal of Medicinal Chemistry, 1999, 42, 4108-4121.	2.9	67
154	Cytotoxic versus genotoxic effects of nitric oxide (NO). Toxicology Letters, 1999, 106, 59-67.	0.4	20
155	Evidence against a role of physiological concentrations of estrogen in post-myocardial infarction remodeling. Journal of the American College of Cardiology, 1999, 34, 1427-1434.	1.2	28
156	Autoinhibition of neuronal nitric oxide synthase: distinct effects of reactive nitrogen and oxygen species on enzyme activity. Biochemical Journal, 1999, 340, 745-752.	1.7	39
157	Autoinhibition of neuronal nitric oxide synthase: distinct effects of reactive nitrogen and oxygen species on enzyme activity. Biochemical Journal, 1999, 340, 745.	1.7	18
158	Multiple Mechanisms are Involved in the Acute Vasodilatory Effect of 17Î²-Estradiol in the Isolated Perfused Rat Heart. Journal of Cardiovascular Pharmacology, 1999, 33, 852-858.	0.8	11
159	Renal toxicity of the neuron-blocking and mitochondriotropic agent m -iodobenzylguanidine. Cancer Chemotherapy and Pharmacology, 1998, 42, 37-45.	1.1	7
160	Pharmacology of NO:cGMP signal transduction. Naunyn-Schmiedeberg's Archives of Pharmacology, 1998, 358, 111-112.	1.4	41
161	Distribution of nitric oxide synthase and nitric oxide-receptive, cyclic GMP-producing structures in the rat brain. Neuroscience, 1998, 87, 207-241.	1.1	143
162	Anti-pterins as Tools to Characterize the Function of Tetrahydrobiopterin in NO Synthase. Journal of Biological Chemistry, 1998, 273, 33142-33149.	1.6	44

#	Article	IF	Citations
163	Localization of nitric oxide synthase, NADPH diaphorase and soluble guanylyl cyclase in adult rabbit retina. Visual Neuroscience, 1998, 15, 881-890.	0.5	45
164	Human soluble guanylate cyclase: functional expression and revised isoenzyme family. Biochemical Journal, 1998, 335, 51-57.	1.7	139
165	Just Say NO to Cancer?. Journal of the National Cancer Institute, 1997, 89, 406-407.	3.0	35
166	Identification of uterine-related sympathetic neurons in the rat inferior mesenteric ganglion: neurotransmitter content and afferent input. Journal of the Autonomic Nervous System, 1996, 59, 51-59.	1.9	31
167	Colocalization of neuronal nitric oxide synthase with GABA in rat cuneate nucleus. Journal of Neurocytology, 1995, 24, 237-245.	1.6	20
168	Nitric oxide nerves in the uterus are parasympathetic, sensory, and contain neuropeptides. Cell and Tissue Research, 1995, 279, 339-349.	1.5	69
169	Induction and variants of neuronal nitric oxide synthase type I during synaptogenesis. FASEB Journal, 1995, 9, 799-806.	0.2	92
170	Thiol Dependence of Nitric Oxide Synthase. Biochemistry, 1995, 34, 13443-13452.	1.2	104
171	Aldehyde fixation differentially affects distribution of diaphorase activity but not of nitric oxide synthase immunoreactivity in rat brain. Brain Research Bulletin, 1995, 38, 467-473.	1.4	46
172	Evidence for bidirectional changes in nitric oxide synthase activity in the rat striatum after excitotoxically (quinolinic acid) induced degeneration. Neuroscience, 1995, 67, 345-356.	1.1	45
173	The extravascular contractile system in the human placenta. Anatomy and Embryology, 1994, 190, 541-8.	1.5	42
174	NO at work. Cell, 1994, 78, 919-925.	13.5	1,519
175	Upregulation of neuronal nitric oxide synthase and mRNA, and selective sparing of nitric oxide synthase-containing neurons after local cerebral ischemia in rat. Brain Research, 1994, 654, 85-95.	1.1	201
176	Neurons in rat hippocampus that synthesize nitric oxide. Journal of Comparative Neurology, 1993, 331, 111-121.	0.9	215
177	Cloned human brain nitric oxide synthase is highly expressed in skeletal muscle. FEBS Letters, 1993, 316, 175-180.	1.3	483
178	Neurons in rat cerebral cortex that synthesize nitric oxide: NADPH diaphorase histochemistry, NOS immunocytochemistry, and colocalization with GABA. Neuroscience Letters, 1993, 157, 157-161.	1.0	214
179	Comments on Meller, S.T. and Gebhart, G.F., PAIN , 52 (1993) 127â€“136. Pain, 1993, 55, 401-402.	2.0	5
180	The nitric oxide and cGMP signal transduction system: regulation and mechanism of action. Biochimica Et Biophysica Acta - Molecular Cell Research, 1993, 1178, 153-175.	1.9	687

#	Article	IF	Citations
181	Nitroxergic autonomic neurones in rat spinal cord. NeuroReport, 1993, 4, 923-926.	0.6	27
182	Insulin secretion from pancreatic B cells caused by L-arginine-derived nitrogen oxides. Science, 1992, 255, 721-723.	6.0	419
183	Mapping of neural nitric oxide synthase in the rat suggests frequent co-localization with NADPH diaphorase but not with soluble guanylyl cyclase, and novel paraneural functions for nitrinergic signal transduction.. Journal of Histochemistry and Cytochemistry, 1992, 40, 1439-1456.	1.3	618
184	Nitric oxide synthase in macula densa regulates glomerular capillary pressure.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 11993-11997.	3.3	492
185	Nitric oxide synthase and GABA colocalize in lamina II of rat spinal cord. Neuroscience Letters, 1992, 148, 6-10.	1.0	143
186	Human brain contains a metalloprotease that converts big endothelinâ€1 to endothelinâ€1 and is inhibited by phosphoramidon and EDTA. British Journal of Pharmacology, 1992, 106, 505-506.	2.7	15
187	Characterization and localization of nitric oxide synthase in nonâ€adrenergic nonâ€cholinergic nerves from bovine retractor penis muscles. British Journal of Pharmacology, 1992, 106, 768-773.	2.7	72
188	Nitric oxide synthase in ferret brain: localization and characterization. British Journal of Pharmacology, 1992, 107, 849-852.	2.7	9
189	Double-edged role of endogenous nitric oxide. Lancet, The, 1992, 339, 986.	6.3	24
190	Nitric oxide synthase immunoreactivity and NADPH-diaphorase activity in a subpopulation of intrinsic neurones of the guinea-pig heart. Neuroscience Letters, 1992, 143, 65-68.	1.0	112
191	Bioassay for EDRF/NO by accumulation of cyclic GMP in RFL-6 fetal rat lung fibroblasts. Methods, 1992, 1, 117-123.	0.5	1
192	Calcium/calmodulin-dependent nitric oxide synthase type I: a biopteroflavoprotein with calcium/calmodulin-independent diaphorase and reductase activities. Biochemistry, 1992, 31, 3243-3249.	1.2	166
193	NOâ€¢, CO andâ€¢OH Endogenous soluble guanylyl cyclase-activating factors. FEBS Letters, 1992, 307, 102-107.	1.3	178
194	Induced RAW 264.7 macrophages express soluble and particulate nitric oxide synthase: inhibition by transforming growth factor-ÃŸ. European Journal of Pharmacology, 1992, 225, 161-165.	2.7	76
195	Endothelial cells have a particulate enzyme system responsible for EDRF formation: Measurement by vascular relaxation. Biochemical and Biophysical Research Communications, 1991, 176, 1417-1423.	1.0	45
196	Purification and characterization of a human NO synthase. Biochemical and Biophysical Research Communications, 1991, 181, 1372-1377.	1.0	112
197	Isoforms of nitric oxide synthase Characterization and purification from different cell types. Biochemical Pharmacology, 1991, 42, 1849-1857.	2.0	813
198	Purification of a soluble isoform of guanylyl cyclase-activating-factor synthase.. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 365-369.	3.3	392

#	Article	IF	Citations
199	Purification and characterization of particulate endothelium-derived relaxing factor synthase from cultured and native bovine aortic endothelial cells.. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 10480-10484.	3.3	897
200	Calmodulin-dependent endothelium-derived relaxing factor/nitric oxide synthase activity is present in the particulate and cytosolic fractions of bovine aortic endothelial cells.. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 1788-1792.	3.3	566
201	Enzymes Synthesizing Guanylate Cyclase-Activating Factors in Endothelial Cells, Neuroblastoma Cells, and Rat Brain. Journal of Cardiovascular Pharmacology, 1991, 17, S57-S64.	0.8	15
202	Characterization and purification of a rat brain enzyme which catalyzes the formation of an EDRF-like factor from L-arginine. European Journal of Pharmacology, 1990, 183, 647-648.	1.7	5
203	Regional distribution of EDRF/NO-synthesizing enzyme(s) in rat brain. Biochemical and Biophysical Research Communications, 1990, 168, 727-732.	1.0	240
204	<scp>l</scp>â€Arginine and arginine analogues: effects on isolated blood vessels and cultured endothelial cells. British Journal of Pharmacology, 1990, 101, 145-151.	2.7	27
205	Enzymatic formation of nitrogen oxides from L-arginine in bovine brain cytosol. Biochemical and Biophysical Research Communications, 1989, 165, 284-291.	1.0	156
206	Formation and release of nitric oxide from human neutrophils and HL-60 cells induced by a chemotactic peptide, platelet activating factor and leukotriene B4. FEBS Letters, 1989, 244, 357-360.	1.3	236
207	Arginine is a physiological precursor of endothelium-derived nitric oxide. European Journal of Pharmacology, 1988, 154, 213-216.	1.7	313
208	Is arginine a physiological precursor of endothelium-derived nitric oxide?. European Journal of Pharmacology, 1988, 148, 293-295.	1.7	73